JPRN-UMIN000042738已完成4 期
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults - Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults
Tokyo Medical University Hospital Travellers' Medical Center0 个研究点目标入组 14 人开始时间: 2021年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Manifest fever (37.5 or more temperature) 2)Suffering from severe acute illness 3)History of anaphylaxis 4)Immunodeficiency 5)HIV infection 6)Immunosuppressive and Immunomodulatory Therapies 7)Neurological disorder 8)Thymus Disorder 9)History of hypersensitivity to MR and yellow fever vaccine 10)Other chronic medical conditions 11)Pregnancy 12)Brestfeeding 13)Other inappropriate condition for vaccination
研究者
相似试验
招募中
4 期
Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adultsPrevention of Yellow fever, Measles and RubellaYellow fever, Measles, RubellaJPRN-jRCT1031210111FUKUSHIMA SHINJI20
进行中(未招募)
1 期
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.EUCTR2022-004118-12-ATMedical University of Vienna256
尚未招募
Unknown
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in MozambiquePoliovirusPACTR202404654347323World Health Organization888
进行中(未招募)
不适用
An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and 12 months of age, and a booster dose at 5½ years of age. - Tdap Booster studyEUCTR2008-008195-13-SESwedish Institute for Infectious Disease Control (SMI)
已完成
不适用
Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaRenal cell carcinomaJPRN-UMIN000014703The University of Tokyo Hospital15
